Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature)

Geneva, Switzerland – 19 September 2018 – We are pleased to announce that AMAL Therapeutics is featured in the September edition of BioPharma Dealmakers (Nature Research), outlining the promise of protein-based therapeutics cancer vaccine in oncology.   View PDF

AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round

Geneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF

TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10

Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]

Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary

Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]

Amal Therapeutics to publish R&D outcomes in Molecular Therapy

Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF

Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board

Geneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF

Amal Therapeutics raises CHF 3 million in a Series A financing round

Geneva, Switzerland, and Ingelheim, Germany, March 30, 2016 – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. View PDF

Amal Therapeutics receives CTI grant to evaluate immunotherapy combination treatments

Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF

US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform

GENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment […]

Amal Therapeutics announces the signature of an Exclusive Patent License Agreement with the University of Minnesota

Geneva, Switzerland, October 27, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties. View PDF